A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 20, Issue 6, 1997, Pages 569-572

  Park, Joon Oh ^a,b   Rha, Sun Young ^a,b   Yoo, Nae Choon ^a,b   Kim, Joo Hang ^a,b   Roh, Jae Kyung ^a,b   Min, Jin Sik ^a,b   Kim, Byung Soo ^a,b   Chung, Hyun Cheol ^a,b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

Chemotherapy induced emesis; Granisetron ondansetron

Indexed keywords

CISPLATIN; DOXORUBICIN; GRANISETRON; ONDANSETRON;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRANISETRON; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NAUSEA; ONDANSETRON; PROSPECTIVE STUDIES; VOMITING;

EID: 0343683288     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199712000-00007     Document Type: Article

References (17)

1. 3 receptor antagonists for chemotherapy-induced emesis. J Clin Oncol 1995;13:1036-43.
2. Borison HL, Borison R, McCarthy LE. Role of the area postrema in vomiting and related functions. Federation Proceedings 1984;43:2955-8.
3. Andrews PLR, Bhandari P. The 5-hydroxytryptamine receptor antagonists as antiemetics: preclinical evaluation and mechanism of action. Eur J Cancer 1993;29A:S11-5.
4. Einhorn LH, Nagy C, Werner K, et al. Ondansetron: a new antiemetics for patients receiving cisplatin chemotheapy. J Clin Oncol 1990;8:731-5.
5. Andrews PLR. The pharmacologic profile of granisetron (Kytril). Semin Oncol 1994;21:3-9.
6. Cupissol DR, Serrou B, Caubel M. The efficacy of granisetron as a prophylactic anti-emetic and intravention agent in high dose cisplatin induced emesis. Eur J Cancer 1990;26A:S23-7.
7. Perez EA, Gandara DR. The clinical role of granisetron (Kytril) in the prevention of chemotherapy induced emesis. Semin Oncol 1994;21:15-21.
8. Navari R, Gandara D, Hesketh P, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. J Clin Oncol 1995;13:1242-8.
9. Navari R, Hesketh P, Grote T, et al. A double-blind randomized, comparative IV study of single dose dolasetron vs ondansetron in preventing cisplatin-related emesis [Abstract]. Proceedings of the American Society of Clinical Oncology 1995;14:522.
10. Italian Group for Antiemetic Research. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 1995;6:805-10.
11. Gebbia V, Cannata G, Testa A, et al. Ondansetron versus granisetron in the prevention of chemotherapy induced nausea and vomiting; results of a prospective randomized trial. Cancer 1994;74:1945-52.
12. The granisetron study group. Dose finding of granisetron in patients receiving high dose cisplatin chemotherapy. Br J Cancer 1994;69:967-71.
13. Noble A, Bremer K, Dilly SG. A double-blind, cross-over comparison of granisetron and ondansetron in 5 days fractionated chemotherapy: assessment of efficacy, safety and patient preference. Eur J Cancer 1994;30A:1083-8.
14. Ruff P, Paska W, Goedhals L, et al. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicenter double-blind, randomized, parallel-group study. Oncology 1994;51:113-8.
15. 3 antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy: A randomized study. Eur J Cancer 1993;29A:1669-72.
16. 3 antagonist, versus a standard anti-emetic regimen of chlorpromazine plus dexamethasone in the treatment of cytostatic-induced emesis. Eur J Cancer 1990;26A:S28-32.
17. Chevallier B. Efficacy and safety of granisetron compared with high dose metoclopramide plus dexamethasone in patients receiving high dose cisplatin in a single-blind study. Eur J Cancer 1990;26A:S33-6.